Then, a company named Regeneron announced they would buy the company, and would “prioritize [consumer data's] privacy, security and ethical use." Now there's been another twist: That company was outbid just before the sale closed,

TTAM replaces biotech company Regeneron as 23andMe's buyer. Last month, Regeneron won the bidding during the bankruptcy auction to purchase 23andMe for $256 million. Wojcicki reop

Me struck a deal last month with Regeneron Pharmaceuticals Inc., but Wojcicki complained about the bidding process, setting the stage for new bids. Correction/Clarification Updated to include the amount of Regeneron's backup bid.